STEPHANIE MAHOOTY: Open Payments
NPI 1922399542 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,472 in 33 payments from 17 companies in 2025. Trend: 2023 $913 · 2024 $517 · 2025 $1,472
Food & beverage: $1,472
| Company | Payments | Amount |
|---|---|---|
| AKEBIA THERAPEUTICS INC | 2 | $233 |
| AstraZeneca Pharmaceuticals LP | 5 | $200 |
| Travere Therapeutics, Inc. | 2 | $145 |
| Novo Nordisk Inc | 2 | $135 |
| Amgen Inc. | 2 | $123 |
| Novartis Pharmaceuticals Corporation | 6 | $122 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $97 |
| NxStage Medical, Inc. | 1 | $96 |
| Otsuka America Pharmaceutical, Inc. | 3 | $86 |
| GENZYME CORPORATION | 1 | $73 |
Products named: Vafseo, LOKELMA, Filspari, Ozempic, KRYSTEXXA, NXSTAGE SYSTEM ONE, Vanrafia, FABRAZYME.
Industry payments across AZ — which companies pay providers there.
